Originally developed to treat type 2 diabetes, semaglutide has gained widespread use for weight management under brand names like Wegovy and Ozempic
Arun Sanyal, M.D., chief of the Division of Gastroenterology, Hepatology and Nutrition and director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health MASH affects around 15 million Americans, and currently there is only one FDA-approved treatment available, increasing the urgency for effective therapeutic options
Pharmacy changes have caused frustration, with some reviewers noting that their pharmacy changed mid-subscription, leading to different medication formulations or packaging
The combination of multiple medications affecting gastrointestinal motility should be carefully evaluated, and patients should be monitored for both efficacy and tolerability
Epidemiology of overweight and obesity in Indian adults-A secondary data analysis of the National Family Health Surveys